FDA issued 3 citations in cities across Alameda County in October

Dr. Namandjé N. Bumpus Principal Deputy Commissioner - FDA
Dr. Namandjé N. Bumpus Principal Deputy Commissioner - FDA
0Comments

There was one company in a city associated with Alameda County that received FDA citations as a result of one inspection conducted in the county in October, according to the U.S. Food and Drug Administration (FDA).

No companies were cited in the previous month.

The citations in the county include:

  • The labels of the medical device(s) do not bear a unique device identifier (UDI) that meet the requirements of 801 Subpart B and 21 CFR 830.
  • An MDR report was not submitted within 30 days of receiving or otherwise becoming aware of information that reasonably suggests that a marketed device has malfunctioned and would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.
  • Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have not been adequately established.

The company cited should take a voluntary action to correct its managing operations.

The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.

According to its website, the FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety and quality.

Companies Located within Alameda County Cities and the Citations They Received in October
Company Name Area of Business Inspection Date Issue Cited
Biogenex Laboratories, Inc. Devices 10/06/2025 Label to bear a unique device identifier
Biogenex Laboratories, Inc. Devices 10/06/2025 Individual Report of Malfunction
Biogenex Laboratories, Inc. Devices 10/06/2025 Lack of or inadequate complaint procedures

Information in this article was obtained from the U.S. Food and Drug Administration. The source data can be found here.



Related

Dr. Mehmet Oz CMS Administrator

Fremont Medicaid claims for Evaluation and Management services rise to $15.7 million in 2024

Medicaid spending associated with the Evaluation and Management category in Fremont increased by 3.1% in 2024, reflecting shifts in reimbursement rates and service use.

Dr. Mehmet Oz CMS Administrator

Union City Medicaid payments for Pathology and Laboratory Procedures rise to $36,695,787 in 2024

Union City Medicaid providers received $36,695,787 for Pathology and Laboratory Procedures in 2024, showing a 31.7% rise from the prior year.

Dr. Mehmet Oz CMS Administrator

Newark Medicaid COVID-19 payments reach $3,780 in 2024, state database shows

In 2024, Medicaid providers in Newark billed at least $3,780 for services categorized under HCPCS codes specifically linked to COVID-19 care, with 31% of such billing recorded during the peak pandemic years of 2020 and 2021.

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from South Alameda News.